<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92278">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01736254</url>
  </required_header>
  <id_info>
    <org_study_id>14701</org_study_id>
    <secondary_id>I1V-MC-EIBD</secondary_id>
    <nct_id>NCT01736254</nct_id>
  </id_info>
  <brief_title>A Study of Evacetrapib in Healthy Participants</brief_title>
  <official_title>Effect of Gemfibrozil on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to measure how much of the study drug (evacetrapib) gets into
      the blood stream and how long it takes the body to get rid of it when given with
      gemfibrozil.  Each participant will receive gemfibrozil alone, evacetrapib alone, and both
      drugs in combination.  There is  no washout period between doses.  The safety of both of the
      study drugs given together will be evaluated. Information about any side effects that may
      occur will also be collected. This study will last approximately 36 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) of Evacetrapib</measure>
    <time_frame>Predose up to 24 hours Post-dose Day 11 and Day 22</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Curve Over a 24 Hour Dosing Interval (AUCτ) of Evacetrapib</measure>
    <time_frame>Predose up to 24 hours Post-dose Day 11 and Day 22</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Time of Maximum Observed Drug Concentration (Tmax) of Evacetrapib</measure>
    <time_frame>Predose up to 24 hours Post-dose Day 11 and Day 22</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Curve Over a 12 Hour Dosing Interval (AUCτ) of Gemfibrozil</measure>
    <time_frame>Predose up to 12 hours Post-dose Day 1 and Day 13</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Gemfibrozil</measure>
    <time_frame>Predose up to 12 hours Post-dose Day 1 and Day 13</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Time of Maximum Observed Drug Concentration (Tmax) of Gemfibrozil</measure>
    <time_frame>Predose up to 12 hours Post-dose Day 1 and Day 13</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Gemfibrozil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of 600 milligrams (mg) gemfibrozil on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evacetrapib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral doses of 130 mg of evacetrapib once a day (QD) for 10 days (Day 2 through Day 12)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evacetrapib + Gemfibrozil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral doses of 600 mg gemfibrozil twice a day (BID) and 130 mg evacetrapib once a day (QD) for 10 days (Day 13 through Day 22).  Single oral dose of 600 mg gemfibrozil on Day 23.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evacetrapib</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Gemfibrozil</arm_group_label>
    <arm_group_label>Evacetrapib + Gemfibrozil</arm_group_label>
    <other_name>LY2484595</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemfibrozil</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Evacetrapib</arm_group_label>
    <arm_group_label>Evacetrapib + Gemfibrozil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy participants as determined by medical history and physical examination

          -  Have a body mass index of 18 to 32 kilograms per square meter (kg/m^2)

        Exclusion Criteria:

          -  Have known allergies to evacetrapib and gemfibrozil, related compounds or any
             components of the formulation

          -  Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of
             the investigator, increases the risks associated with participating in the study

          -  Regularly use known drugs of abuse and/or show positive findings on urinary drug
             screening

          -  Currently smoke cigarettes or use tobacco or nicotine substitutes
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 14, 2013</lastchanged_date>
  <firstreceived_date>November 26, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gemfibrozil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
